Home
About
Overview
Sharing Data
ORCID
Help
History (3)
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101.
Peripheral artery disease, biomarkers, and darapladib.
The Legionella pneumophila major secretory protein, a protease, is not required for intracellular growth or cell killing.
See All 3 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Peripheral artery disease, biomarkers, and darapladib.
Peripheral artery disease, biomarkers, and darapladib. Am Heart J. 2011 May; 161(5):972-8.
View in:
PubMed
subject areas
1-Alkyl-2-acetylglycerophosphocholine Esterase
Aged
Benzaldehydes
Biomarkers
Disease Progression
Dose-Response Relationship, Drug
Double-Blind Method
Female
Follow-Up Studies
Humans
Male
Middle Aged
Oximes
Peripheral Arterial Disease
Retrospective Studies
Risk Factors
Survival Rate
Treatment Outcome
authors with profiles
Michael H. Davidson